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Abstract
Background Several studies have shown that when patients with functional neurological disorders are followed up, it is 
rare to find another neurological condition that better explains the initial symptoms in hindsight. No study has examined the 
reverse, studying patients with a range of neurological disease diagnoses with the aim of assessing how often a new diagnosis 
of functional disorder better explains the original symptoms.
Methods A prospective multi-centre cohort study of 2637 new neurology outpatient referrals from primary care in Scotland. 
Neurologists provided initial diagnoses and a rating of the extent to which their symptoms were explained by an ‘organic’ 
neurological disease. Patients were followed up 19 months later with a questionnaire to their primary care physician ask-
ing about diagnostic change, and when indicated also by discussion with the original assessing neurologist and review of 
secondary care records.
Results Valid responses were obtained for 2378 out of 2637 patients (90%) with symptoms ‘largely’ or ‘completely’ explained 
by organic disease at baseline. At follow-up, we found diagnostic errors in 48 patients. Of those, ten (0.4%) had a functional 
diagnosis and 38 patients (1.6%) had a different ‘organic’ diagnosis which better explained the original symptoms.
Conclusions Patients diagnosed with neurological disease sometimes have a functional diagnosis at follow-up which, with 
hindsight, better explains the original symptoms. This occurs at a frequency similar to the misdiagnosis of ‘organic’ neu-
rological disease as functional disorder. Misdiagnosis can harm patients in either direction, especially as we enter an era of 
evidence-based treatment for functional neurological disorders.
Keywords Functional neurological disorders · Psychogenic · Conversion disorder · Misdiagnosis
Introduction
One-third of patients in Scottish general neurology clinics 
were rated by neurologists as having symptoms ‘somewhat’ 
or ‘not at all’ explained by recognised neurological disease 
[1]. These patients had outcomes and levels of disability and 
distress marginally worse than outpatients with symptoms 
‘largely’ or ‘completely’ attributed to ‘organic’ disease [2, 
3]. In an earlier publication from the Scottish Neurologi-
cal Symptom Study (SNSS) involving 3781 patients, we 
showed that when these patients were followed up in pri-
mary care, it was rare to find a neurological disease which 
better explained the original presentation over a 19 month 
period [1].
Here, we address the opposite question. When patients 
originally diagnosed with an ‘organic’ neurological disease 
are followed up, how often is there evidence at follow-up of 
a functional disorder that, with hindsight, better explains the 
original symptoms?
This question has traditionally been less of a concern for 
neurologists, but as we accumulate evidence-based treatment 
for functional disorders, and recognise good treatment out-
comes in many patients, this view requires reconsideration. 
Studies in specific disease areas such as stroke, epilepsy, and 
multiple sclerosis have identified that functional disorders 
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are a commonly overlooked cause of diagnostic error [4–9]. 
There has, however, been no study across representative neu-
rological practice to look at how commonly misdiagnosis 
occurs in this direction.
In this study, we aimed to determine the frequency of 
misdiagnosis of functional disorders as recognised neurolog-
ical disease, along with other diagnostic revisions in patients 
classified by neurologists has having symptoms ‘completely’ 
or ‘largely’ explained by ‘organic’ neurological disease.
Methods
Patients
Between December 2002 and February 2004, new patients 
at National Health Service (NHS) neurology clinics in Scot-
land (population 5,057,400 at the time of the study) were 
eligible for inclusion in the SNSS, a multi-centre prospec-
tive cohort study. Referrals came mainly from primary care. 
Tertiary clinics and ‘urgent case’ emergency clinics were 
excluded. Patients were excluded if they were: less than 
16 years old; had cognitive or physical impairment impairing 
consent; were unable to read English; or if the neurologist 
found them unsuitable to take part in the study, for example, 
because they were too distressed or terminally ill. Patients 
were excluded if they did not give informed consent. Ethi-
cal approval for this study was granted by UK Multicentre 
Research Ethics Committee.
Baseline assessment
After seeing each patient, neurologists were asked to give up 
to three diagnoses accounting for their symptoms. They were 
also asked to rate: ‘To what extent do you think this patient’s 
clinical symptoms are explained by organic disease?’ on a 
four-point Likert-type scale ranging from symptoms ‘com-
pletely’, ‘largely’, ‘somewhat’ or ‘not at all’ explained by 
‘organic’ disease. In retrospect, we recognise that the term 
‘organic’ is meaningless, as all symptoms must have a bio-
logical basis [10], and we might have better said ‘a recog-
nised pathophysiological disease’ or some similar wording. 
However, we have kept with the original terminology, which 
was operationalised for the study (see Online Resource 1). 
We also would like to emphasise that we personally regard 
each of these categories representing patients with genuine 
and disabling conditions, as our other studies have shown 
[3].
Follow‑up assessment
Patients were followed up on average 19 months after they 
were seen in clinic in four ways. First, patients’ general 
practitioners (GPs) were sent a questionnaire with their 
patient’s baseline diagnoses and ‘organicity’ rating, and 
they were asked to report: 1) if any new clinical events had 
occurred; 2) if so, what they were; and 3) in the GP’s opin-
ion, whether these are a better explanation for the original 
symptoms. Second, patient deaths were identified from 
NHS Scotland’s Information Services Division’s database 
and death certificates. Third, where further clarification was 
needed, a letter was sent to the original neurologist asking 
whether: 1) they agree with the GP’s assessment; 2) they 
have evidence they suspected this diagnosis on the first clinic 
visit; and 3) they had further information. Finally, where 
necessary, the patients’ GPs were contacted, and original 
clinic letters were reviewed for further clarification.
Analysis
Patients who had a possible better explanation for their 
original presentation were identified from GP responses 
and by reviewing patient data. They were separated into 
those whose diagnosis had changed from ‘organic’ to func-
tional, and those whose diagnosis had changed but remained 
‘organic’. For the criteria, we used to define ‘organic’ and 
‘functional’ diseases at follow-up, see Online Resource 1.
Not all instances of diagnostic change represent a clinical 
error. Patients were further categorised based on the type 
of diagnostic revision using our previous classification [1] 
(Table 1). A Category 1 diagnostic revision reflects a diag-
nostic error, whereby the new diagnosis could have been 
recognised at the onset, but was not; Category 2–8 diagnos-
tic revisions reflect minor or no clinician error (Table 1).
Patients whom we categorised as having undergone 
Category 1 ‘organic’ to functional diagnostic change were 
assigned a confidence rating based on researcher consensus 




Of 5369 eligible patients in SNSS, 3781 were included in the 
study sample (Fig. 1). A detailed breakdown of diagnoses 
in all 3781 new clinic presentations is published elsewhere 
[11]. 1144 patients, whose symptoms at baseline were rated 
as being ‘somewhat’ or ‘not at all’ explained by ‘organic’ 
neurological disease, were excluded from this study and are 
reported elsewhere [1].
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Diagnostic change
The median interval between initial neurology appoint-
ment and receiving follow-up data from GPs was 577 days 
(interquartile range 535–601 days). Valid responses were 
received for 2378 of 2637 patients with ‘organic’ (‘largely’ 
or ‘completely’ explained by disease) diagnoses at baseline 
(90% response rate) (Fig. 2). Invalid responses comprised 
instances where GPs did not respond, where they responded, 
but did not provide any information about their patient, or 
where the patient had left their practice.
New clinical events were reported in 453 patients, of 
whom 199 had a new clinical event at follow-up which was 
a possible better explanation for their original presentation 
than their baseline diagnosis (Fig. 2). New clinical events 
were ‘organic’ in 184 of these patients. Of these, 38 (1.6% 
of patients with baseline symptoms ‘completely’ or ‘largely’ 
explained by disease) were Category 1 diagnostic revisions 
and three had died; most of the rest underwent Categories 
3–8 diagnostic revisions (Online Resource 2). 18 were 
excluded, because although their GPs reported a new clini-
cal event which better explained their original presentation, 
they either did not state what it was or did not report a new 
diagnosis (Online Resource 2).
New clinical events were functional disorders in 15 
patients (Fig.  2), of whom ten (0.4% of patients with 
baseline symptoms ‘completely’ or ‘largely’ explained 
by disease) had undergone Category 1 diagnostic revi-
sions, classified as ‘definite’ (n = 5), ‘probable’ (n = 1), 
and ‘possible’ (n = 4) diagnostic error (Table 2). Of those 
ten patients, six had follow-up diagnoses of anxiety or 
depression, two had dissociative (non-epileptic) seizures, 
one had chronic fatigue syndrome, and one had fibromy-
algia, which appeared to better explain a range of pre-
senting symptoms. Three patients with anxiety or chronic 
fatigue syndrome were misdiagnosed with multiple scle-
rosis or ‘demyelination’, and two patients with dissocia-
tive (non-epileptic) seizures were misdiagnosed with epi-
leptic seizures. The diagnostic revisions of the remaining 
five patients were Categories 2–8 and thus not classed as 
diagnostic error: of these, there was one instance of de 
novo development of a new condition and four instances 
of disagreement between doctors (Table 2).
In summary, out of 2378 patients with an ‘organic’ 
baseline diagnosis whom we were able to follow up, 48 
Table 1  Classification of diagnostic revisions adapted from our previous classification [1]
Type of diagnostic revision Example Degree of clinician error
1 Diagnostic error Patient presented with symptoms that were plausibly due to fibromyalgia. 
The diagnosis of fibromyalgia had not been considered and was unex-
pected at follow-up
Major
2 Differential diagnostic change Patient presented with symptoms that were plausibly related to a number 
of conditions. Doctor considered multiple sclerosis and chronic fatigue 
syndrome as possible diagnoses. Appropriate investigations and follow-
up confirmed chronic fatigue syndrome
None to minor
3 Diagnostic refinement Doctor diagnosed epilepsy but at follow-up the diagnosis was refined to 
juvenile myoclonic epilepsy.
Minor
4 Comorbid diagnostic change Doctor correctly identified the presence of both epilepsy and non-epilep-
tic seizures in the same patient. At follow-up, one of the disorders had 
remitted
None
5 Prodromal diagnostic change Patient presented with optic neuritis. At follow-up the patient has multiple 
sclerosis. With hindsight, optic neuritis was a prodromal symptom of 
multiple sclerosis but the diagnosis could not have been made at the 
initial consultation as the subsequent symptoms (or findings on exami-
nation or investigation) had not developed
None
6 De novo development of new condition Patient is correctly diagnosed with epilepsy. During the period of follow-
up, the patient develops fibromyalgia as a completely new condition
None
7 Disagreement between doctors—with-
out new information at follow-up
Patient is diagnosed at baseline with chronic Lyme disease and at follow-
up with chronic fatigue syndrome by a different doctor even though 
there is no new information. At follow-up, both doctors would still 
have arrived at the same diagnoses, reflected in similar divided opinion 
among their peers
None
8 Disagreement between doctors—with 
new information at follow-up
Patient is diagnosed at baseline with chronic Lyme disease and at follow-
up with chronic fatigue syndrome by a different doctor on the basis that 
there was no positive serology for Lyme disease. Both doctors would 
still have arrived at the same diagnoses, reflected in similar divided 
opinion among their peers
None
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(2%) had a Category 1 misdiagnosis at follow-up. Of 
these, 38 (1.6%) patients’ diagnoses changed to a different 
‘organic’ disease, and 10 (0.4%) changed from ‘organic’ 
disease to a functional disorder.
Discussion
The strength of this study comes from its large sample size 
of 3781 patients across all four Scottish neurology centres. 
Almost all (36/38) Scottish consultant neurologists working 
at the time participated.
Fig. 1  Patient recruitment into study; adapted from our previous publication [1]
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Fig. 2  Response rate and subsequent diagnostic revision, on the basis of GP follow-up data, of 2637 patients diagnosed with symptoms ‘com-
pletely’ or ‘largely’ explained by ‘organic’ disease at initial consultation
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Data on patients from the SNSS cohort who had symp-
toms not explained by ‘organic’ disease at baseline are 
published elsewhere [1]; of these, four (0.4%) acquired 
an unexpected new ‘organic’ diagnosis which provided a 
better explanation for their first presentation. In this new 
analysis, the proportion of patients with ‘organic’ diagnoses 
who were misdiagnosed with a functional disorder was the 
same (0.4%). As a result of a higher denominator, the abso-
lute number of patients misdiagnosed as having ‘organic’ 
disease was roughly double that of those misdiagnosed in 
the other direction. In addition, the absolute numbers of 
patients where a DSM-5-defined functional neurological 
disorder (FND) was missed were small [only two patients 
with dissociative (non-epileptic) seizures out of 15]. How-
ever, this mirrored our previous study, where only one of the 
four patients erroneously diagnosed with functional disor-
ders had DSM-5-defined FND. We do not wish to encourage 
complacency. In a separate review, we have explored many 
pitfalls in both the diagnosis and misdiagnosis of functional 
disorders which are not represented in this study, and vigi-
lance is always required [12].
Misdiagnosis of functional disorders as ‘organic’ 
disease in neurology
Functional disorders can present with symptoms that super-
ficially resemble many recognised neurological diseases. 
Across studies, 2–71% of people with ‘epilepsy’ are mis-
diagnosed [4]; in these patients, dissociative (non-epilep-
tic) seizures are a common diagnosis in adults, even when 
electroencephalography is used to confirm the diagnosis 
[4]. Similarly, misdiagnosis of multiple sclerosis is com-
mon (estimated 5–10%) [5], with functional disorders often 
reported as the commonest final diagnosis, followed by 
migraine and non-specific white matter lesions on MRI [6, 
9]. Approximately one quarter of stroke presentations are 
‘stroke mimics’ [7], of which functional disorders, migraine, 
and epilepsy are the commonest final diagnoses [7, 8]. By 
contrast, a systematic review of studies where functional 
disorders had been erroneously diagnosed in people with 
neurological disease found that the rate had been 4% since 
1970 [13].
There tends to be more concern about ‘missing’ an 
‘organic’ disease when diagnosing functional disorders, 
rather than the other way around, probably related to a per-
ception, incorrect in our view, that neurological diseases are 
always more serious than functional disorders.
There are obvious and serious implications of missing an 
‘organic’ diagnosis, but the harms of missing a functional 
disorder should not be underestimated in relation to unnec-
essary treatment, delay in treating the underlying functional 
disorder, and psychological harm as a direct result of the 
misdiagnosis.
For example, a study of 110 patients misdiagnosed with 
multiple sclerosis due to various alternative conditions found 
that 33% of patients carried their wrong diagnosis for more 
than 10 years and 31% experienced unnecessary morbidity 
as a result of misdiagnosis, most commonly due to unneces-
sary immunomodulatory therapy and treatment side effects 
[6]. Similarly, treatment with anti-epileptic drugs (AEDs) 
is associated with side effects and potential teratogenicity. 
In a study of 288 patients with dissociative (non-epileptic) 
seizures, 154 (53%) patients were being treated with AEDs 
despite only 32 (11%) having concurrent epilepsy [14]. A 
retrospective study of 85 patients with dissociative (non-epi-
leptic) seizures found that over a quarter had been admitted 
to intensive care at least once due to a mistaken presumed 
status epilepticus [15].
In recent years, it has become clearer that the diagnosis 
of a functional neurological disorder is not one of exclusion 
and should be made on positive grounds, such as Hoover’s 
sign of functional leg weakness or typical features of a dis-
sociative attack. Better characterisation like this has also 
led to promising evidence for the treatment of functional 
neurological disorders, which means that missing them diag-
nostically also potentially means a missed opportunity for 
improvement. A study of mixed patients with functional dis-
orders with brief guided self-help showed promising results 
[16]. A randomised controlled trial (RCT) of physiotherapy 
for functional motor symptoms has shown improvements in 
mobility sustained at 6 month follow-up [17]. A pilot RCT 
found that patients with dissociative (non-epileptic) seizures 
benefitted from cognitive behavioural therapy [18]. In our 
study, although only two of the patients with functional dis-
orders at follow-up had FND, the rest still had evidenced-
based treatable conditions such as anxiety, depression, or 
fibromyalgia.
Considerable psychological harm can come from misdi-
agnosis. Living life under the belief that you have a degen-
erative neurological disease can have profound effects on 
someone’s identity and life course. Being misdiagnosed with 
epilepsy can impact patients’ legal driving status, potentially 
more than dissociative (non-epileptic) attacks in many coun-
tries, and restricts employment [4], with significant psycho-
logical and socio-economic consequences. It is worth noting 
that this is not only the case for patients, where the follow-up 
diagnosis is a functional disorder; there were also misdiag-
noses of similarly ‘impactful’ diseases, to a lesser extent, 
in some ‘organic to organic’ misdiagnosed patients (Online 
Resource 2).
After any diagnosis, whether of a functional disorder 
or a pathological neurological disease, many patients 
undergo a process of identity negotiation, including 
embarrassment of having the condition, concealing the 
condition, and dealing with misconceptions. Eventually, 
the perceived negative impact of the diagnosis may be 
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mediated by the patient normalising and taking owner-
ship of it [19]. This deeply ingrained process can make 
it very difficult to change back a diagnosis once made, 
especially when diagnostic revision happens long after 
the original diagnosis. Indeed, it is difficult for neurolo-
gists to remove a diagnosis like multiple sclerosis without 
causing yet more harm to the patient [20, 21]. In a survey 
of 122 neurologists, two-thirds responded that they find 
‘undiagnosing’ multiple sclerosis more challenging than 
diagnosing it [22].
Limitations
We obtained our follow-up data on limited information 
from patients’ GPs responses and associated correspond-
ence, and not by systematic re-evaluation of patients. The 
follow-up period of 19 months is relatively short, and 
many conditions may take longer to emerge. In addition, 
the data may not generalise to other health care systems.
The study likely underestimates rates of misdiagnosis 
from patients who did not re-attend, or in whom the GP 
had no reason to question the original diagnosis. In addi-
tion, removing a diagnosis like multiple sclerosis is dif-
ficult [20–22], and many neurologists find dealing with 
functional neurological disorders particularly challenging 
[23]. It may be easier to ‘undiagnose’ a functional disor-
der in favour of an ‘organic’ one, for pragmatic and social 
bias reasons. Patients with both ‘organic’ and functional 
disorders, who are not unusual in neurological services 
[24], may have been preferentially diagnosed with the 
‘organic’ disease, because of a tendency of many doc-
tors to place structural diseases first in a hierarchy of 
diagnoses.
Patients in this study were all new referrals to neurolo-
gist clinics, but inevitably many of them had pre-existing 
neurological conditions. We did not collect data on what 
investigations patients had had prior to referral, although 
most were referrals from primary care who would not 
have had brain scans yet. This was a study of outpatient 
neurology, so acute conditions that present as urgent are 
under-represented. Because tertiary clinics were excluded 
from the study, some diseases which were mainly seen 
in specialised clinics in Scotland at that time, such as 
stroke, are also under-represented. This helps explain why 
there were no stroke mimics among the 15 misdiagnosed 
patients in this study, even though they are well described 
in the literature.
Because it relied on researcher judgement, there was 
inevitably some subjectivity involved with our classifica-
tion of patients’ diagnostic revisions; we minimised the 
effect of this by discussing any ambiguities in consensus 
meetings. We did not validate the inter-rater reliability of 
our four-point ‘organicity’ scale, although there was rela-
tive consistency across the four centres and follow-up data 
have suggested that the overwhelming majority of patients 
remained in their initial category.
Conclusion
Neurologists must often deal with high levels of diagnos-
tic uncertainty, and misdiagnoses are, to some extent, an 
inevitable consequence of medical practice. However, the 
concern of getting it wrong should not, in our view, be 
biased against any particular condition, especially if that 
bias prevents a patient receiving evidence-based treatment.
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